ORIC Pharmaceuticals (NASDAQ: ORIC) recently received a number of ratings updates from brokerages and research firms:
- 9/18/2024 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
- 9/10/2024 – ORIC Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
- 9/9/2024 – ORIC Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
- 9/6/2024 – ORIC Pharmaceuticals is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $20.00 price target on the stock.
- 8/14/2024 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
- 8/13/2024 – ORIC Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $17.00 to $15.00. They now have an “outperform” rating on the stock.
- 8/12/2024 – ORIC Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
ORIC Pharmaceuticals Stock Performance
ORIC Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, reaching $11.17. The company’s stock had a trading volume of 318,882 shares, compared to its average volume of 530,005. The firm’s fifty day moving average price is $10.04 and its two-hundred day moving average price is $10.06. The company has a market capitalization of $753.10 million, a P/E ratio of -6.21 and a beta of 1.12. ORIC Pharmaceuticals, Inc. has a 12-month low of $5.27 and a 12-month high of $16.65.
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). On average, research analysts predict that ORIC Pharmaceuticals, Inc. will post -1.78 EPS for the current fiscal year.
Hedge Funds Weigh In On ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Featured Articles
- Five stocks we like better than ORIC Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Ride Out The Recession With These Dividend KingsĀ
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- 3 Best Fintech Stocks for a Portfolio Boost
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for ORIC Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.